AU2002219021A1 - Variant growth hormone molecules conjugated with macromolecular compounds - Google Patents

Variant growth hormone molecules conjugated with macromolecular compounds

Info

Publication number
AU2002219021A1
AU2002219021A1 AU2002219021A AU2002219021A AU2002219021A1 AU 2002219021 A1 AU2002219021 A1 AU 2002219021A1 AU 2002219021 A AU2002219021 A AU 2002219021A AU 2002219021 A AU2002219021 A AU 2002219021A AU 2002219021 A1 AU2002219021 A1 AU 2002219021A1
Authority
AU
Australia
Prior art keywords
growth hormone
macromolecular compounds
molecules conjugated
hormone molecules
variant growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002219021A
Inventor
Kim Vilbour Andersen
Jesper Christiansen
Jorn Drustrup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maxygen ApS
Maxygen Holdings Ltd
Original Assignee
Maxygen ApS
Maxygen Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen ApS, Maxygen Holdings Ltd filed Critical Maxygen ApS
Publication of AU2002219021A1 publication Critical patent/AU2002219021A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
AU2002219021A 2001-01-11 2002-01-10 Variant growth hormone molecules conjugated with macromolecular compounds Abandoned AU2002219021A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26141101P 2001-01-11 2001-01-11
DKPA200100042 2001-01-11
US60/261,411 2001-01-11
DKPA200100042 2001-01-11
PCT/DK2002/000017 WO2002055532A2 (en) 2001-01-11 2002-01-10 Variant growth hormone molecules conjugated with macromolecular compounds

Publications (1)

Publication Number Publication Date
AU2002219021A1 true AU2002219021A1 (en) 2002-07-24

Family

ID=26068940

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002219021A Abandoned AU2002219021A1 (en) 2001-01-11 2002-01-10 Variant growth hormone molecules conjugated with macromolecular compounds

Country Status (4)

Country Link
EP (1) EP1352062A2 (en)
JP (1) JP2004524020A (en)
AU (1) AU2002219021A1 (en)
WO (1) WO2002055532A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
BR0214451A (en) * 2001-11-20 2006-05-30 Pharmacia Corp chemically modified human growth hormone conjugates
AU2003254641A1 (en) * 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
JP2008502301A (en) * 2003-10-10 2008-01-31 ノボ ノルディスク アクティーゼルスカブ Peptide conjugation
CA2552043A1 (en) * 2004-01-21 2005-08-04 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
NZ555386A (en) * 2004-12-22 2011-01-28 Ambrx Inc Formulations of human growth hormone comprising a non-naturally encoded amino acid
JP2008543297A (en) * 2005-06-15 2008-12-04 ノボ ノルディスク ヘルス ケア アーゲー Conjugation of growth hormone via transglutaminase
JP2009506096A (en) 2005-08-30 2009-02-12 ノボ ノルディスク ヘルス ケア アーゲー Liquid preparation of pegylated growth hormone
EP2040757A2 (en) 2006-07-07 2009-04-01 Novo Nordisk Health Care AG New protein conjugates and methods for their preparation
LT3050576T (en) * 2008-04-29 2021-07-12 Ascendis Pharma Endocrinology Division A/S Pegylated recombinant human growth hormone compounds
WO2010015668A1 (en) 2008-08-06 2010-02-11 Novo Nordisk A/S Conjugated proteins with prolonged in vivo efficacy
AU2010207725B2 (en) 2009-01-22 2015-06-11 Novo Nordisk Health Care Ag Stable growth hormone compounds
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
CA2787895A1 (en) * 2010-01-22 2011-07-28 Novo Nordisk Health Care Ag Stable growth hormone compounds
AU2011208625C1 (en) 2010-01-22 2022-08-18 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
WO2012010516A1 (en) 2010-07-22 2012-01-26 Novo Nordisk Health Care Ag Growth hormone conjugates
WO2014139994A1 (en) 2013-03-11 2014-09-18 Novo Nordisk Health Care Ag Growth hormone compounds
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
EP3303380B1 (en) 2015-06-02 2020-01-15 Novo Nordisk A/S Insulins with polar recombinant extensions
MA43348A (en) 2015-10-01 2018-08-08 Novo Nordisk As PROTEIN CONJUGATES
CN114835797A (en) * 2015-11-16 2022-08-02 Ubi蛋白公司 Method for extending protein half-life
EP3606560A2 (en) 2017-04-05 2020-02-12 Novo Nordisk A/S Oligomer extended insulin-fc conjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0458064B1 (en) * 1990-05-04 1998-02-25 American Cyanamid Company Stabilization of somatotropins by modification of cysteine residues
WO1995011987A1 (en) * 1993-10-29 1995-05-04 Incyte Pharmaceuticals, Inc. Chimeric proteins including protease nexin-1 variants
DK1568772T3 (en) * 1995-09-21 2010-10-18 Genentech Inc Variants of Human Growth Hormone
ES2297889T3 (en) * 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. DERIVATIVES OF HORMONE OF GROWTH AND RELATED PROTEINS.
CA2359345A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues

Also Published As

Publication number Publication date
JP2004524020A (en) 2004-08-12
WO2002055532A3 (en) 2002-09-19
EP1352062A2 (en) 2003-10-15
WO2002055532A2 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
AU2002219021A1 (en) Variant growth hormone molecules conjugated with macromolecular compounds
AU2002342653A1 (en) Modified growth hormone
AU2002234854A1 (en) An improved patch panel
AU7578600A (en) Multi-dose syringe driver
AU2002352688A1 (en) Telecommunications patch panel
AU5628600A (en) Insulin-like growth factor agonist molecules
AU7538300A (en) Dual-band microstrip antenna
AU7760500A (en) Pavement patch material
AU5062900A (en) Radio terminal for browsing the internet
AU2003299189A1 (en) Patch
AUPQ339899A0 (en) Novel molecules
AU2001277618A1 (en) Saw device with integral patch antenna
AU2002331681A1 (en) Treatment patch
AU7030200A (en) Edgings
AU3479000A (en) Dermatological patch
AU2001292786A1 (en) Sulfur-containing cathode
AU2001236306A1 (en) Tuneable antenna
AU2001245888A1 (en) Growth factor binding molecules
AU2002311389A1 (en) Crosslinkable composition
AU7829100A (en) Low profile tunable antenna
EP2520289B8 (en) Norethisterone-containing patch
AU2002213723A1 (en) Capacitively switched matrixed el display
AU7306300A (en) Bottle with pump
AU6319600A (en) Patch
AU7060300A (en) Internet jack

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase